ArticleJournal of virology2006
Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides.
Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- Nanosized Shikonin Disrupts Tumor-Cell Mismatch Repair and Synergizes with Manganese to Sensitize Squamous Carcinoma to Immunotherapy.ACS nano · 2025Article
- Development of a stable Sf9 insect cell line to produce VSV-G pseudotyped baculoviruses.Gene therapy · 2024Article
- Article
- The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health.Viruses · 2022Review
- Circumsporozoite Protein ofPharmaceutics · 2022Article
- Baculoviruses in Gene Therapy and Personalized Medicine.Biologics : targets & therapy · 2021Review
- Recent progress in LyP-1-based strategies for targeted imaging and therapy.Drug delivery · 2019Review
- Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins.Virologica Sinica · 2019Article
- The Major Hurdle for Effective Baculovirus Transduction into Mammalian Cells Is Passing Early Endosomes.Journal of virology · 2019Article
- Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model.Journal of biological engineering · 2019Article
- Molecular tumor targeting of gelonin by fusion with F3 peptide.Acta pharmacologica Sinica · 2017Article
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Combinatorial peptide libraries: mining for cell-binding peptides.Chemical reviews · 2014Review
- Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Trial watch: Oncolytic viruses for cancer therapy.Oncoimmunology · 2013Article
- Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Spider silk-based gene carriers for tumor cell-specific delivery.Bioconjugate chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cells and vasculature offer specific targets for the selective delivery of therapeutic genes. To achieve tumor-specific gene transfer, baculovirus tropism was manipulated by viral envelope modification using baculovirus display technology. LyP-1, F3, and CGKRK tumor-homing peptides, originally identified by in vivo screening of phage display libraries, were fused to the transmembrane anchor of vesicular stomatitis virus G protein and displayed on the baculoviral surface. The fusion proteins were successfully incorporated into budded virions, which showed two- to fivefold-improved binding to human breast carcinoma (MDA-MB-435) and hepatocarcinoma (HepG2) cells. The LyP-1 peptide inhibited viral binding to MDA-MB-435 cells with a greater magnitude and specificity than the CGKRK and F3 peptides. Maximal 7- and 24-fold increases in transduction, determined by transgene expression level, were achieved for the MDA-MB-435 and HepG2 cells, respectively. The internalization of each virus was inhibited by ammonium chloride treatment, suggesting the use of a similar endocytic entry route. The LyP-1 and F3 peptides showed an apparent inhibitory effect in transduction of HepG2 cells with the corresponding display viruses. Together, these results imply that the efficiency of baculovirus-mediated gene delivery can be significantly enhanced in vitro when tumor-targeting ligands are used and therefore highlight the potential of baculovirus vectors in cancer gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.